Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Myriad Genetics (NASDAQ: MYGN) will present four research abstracts at the Society of Gynecologic Oncology Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will present four research abstracts at the Society of Gynecologic Oncology Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.

Key highlights: Precise MRD data showed post‑adjuvant ctDNA levels were significantly prognostic of ovarian cancer recurrence; three additional studies use the Myriad Collaborative Research Registry™ with de‑identified data from >1.3 million participants. Presentations and posters occur April 11–13; Myriad will exhibit at booth #523.

Argus Apr 9 session

-6.92% close to close Open Argus

Details

News Market Reaction – MYGN

On Apr 9, the day this news came out, MYGN closed 6.92% below the previous close.

Data tracked by StockTitan Argus for the Apr 9 session.

Market Context

On Apr 9, the day this news came out, the stock closed 6.9% below the previous close. A negative rea...

Analysis

On Apr 9, the day this news came out, the stock closed 6.9% below the previous close. A negative reaction despite this clinically focused news would contrast with earlier data‑driven announcements that generally saw aligned or mildly positive moves, with only the FDA CDx approval drawing a -2.93% decline. The SGO presentations extend the Precise MRD story and leverage a registry of more than 1.3 million participants, but shares remain below the $6.08 200‑day MA and the existing $200,000,000 shelf could add an overhang if investors focus on potential capital raises.

Key Figures

Abstracts at SGO: 4 abstracts MCRR participants: more than 1.3 million participants SGO meeting dates: April 10–13 +5 more

Abstracts at SGO

4 abstracts

Two oral presentations and two posters at SGO Annual Meeting

MCRR participants

more than 1.3 million participants

Myriad Collaborative Research Registry pan‑cancer database

SGO meeting dates

April 10–13

Society of Gynecologic Oncology Annual Meeting schedule

Booth number

523

Myriad’s exhibit location at SGO Annual Meeting

Poster board

1590

Precise MRD ovarian cancer recurrence poster board number

Poster board

1450

Ovarian cancer variants and ancestry poster board number

Session time

Sun., April 12, 12:00–1:00 pm AST

Precise MRD ovarian cancer recurrence poster session

Rapid Fire slot

3:05–3:08 pm AST

Rapid Fire Oral I: Genetics Prevention and Surgery session

Historical Context

5 past events · Latest: Mar 17

5 events

1. Mar 17

   FDA CDx approval

   24h Move

   -2.9%

   FDA approved MyChoice CDx as Zejula companion diagnostic in ovarian cancer.

2. Mar 02

   Product launch

   24h Move

   +5.6%

   Commercial launch of Precise MRD with select community oncologists for breast cancer.

3. Feb 24

   Clinical data abstracts

   24h Move

   +1.1%

   Six ASCO‑GU abstracts on Precise MRD, Prolaris, and MyRisk clinical performance.

4. Feb 23

   Earnings, guidance

   24h Move

   +1.1%

   Q4 and 2025 results with $824.5M revenue and reiterated 2026 guidance and margins.

5. Feb 19

   Test validation data

   24h Move

   +0.2%

   FirstGene prenatal screen showed ≥98.2% sensitivity and ≥99.0% specificity across components.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular residual disease, ctDNA, ultrasensitive assay, germline pathogenic, +4 more

8 terms

molecular residual disease medical

"Evaluation of the Relationship of Molecular Residual Disease Testing to Ovarian"

Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these measurements can predict relapse, guide whether additional therapy is needed, and shape the market for diagnostics and drugs—much like finding embers after a fire helps decide if more firefighting is required.

ctDNA medical

"recurrence risk tracked with the quantitative ctDNA fraction detected by Precise MRD"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

ultrasensitive assay medical

"risk observed even at ctDNA levels detectable only by an ultrasensitive assay"

An ultrasensitive assay is a laboratory test designed to detect extremely small amounts of a biological marker—such as a protein, virus fragment, or antibody—well below the limits of standard tests. For investors it signals technology that can enable earlier disease detection, more precise drug monitoring, smaller sample requirements and new diagnostic markets; think of it as a high-powered magnifying glass that reveals clinical and commercial opportunities others might miss.

germline pathogenic medical

"Germline pathogenic and likely pathogenic variant prevalence is associated with age"

A germline pathogenic change is an inherited DNA mutation present in reproductive cells that increases the likelihood of developing a disease and can be passed to future generations. For investors, this matters because such inherited mutations shape demand for genetic testing, long‑term treatment markets, preventive care and regulatory scrutiny—think of it like a defective blueprint passed down the family line that creates predictable, multi‑generation clinical and commercial implications.

lynch syndrome medical

"Ovarian cancer diagnosis varies by Lynch syndrome gene, informing counseling"

An inherited genetic condition that greatly raises a person’s lifetime risk of certain cancers, most often colorectal and endometrial cancer. It occurs when a cell’s “spell-check” for DNA errors is faulty, making tumors more likely and often changing how cancers are screened and treated; that matters to investors because it drives demand for genetic testing, targeted therapies, screening services and can affect healthcare costs and biotech company prospects.

hereditary cancer screening medical

"Universal hereditary cancer screening identifies more individuals at high risk"

Hereditary cancer screening is a medical test that looks for inherited changes in a person’s genes that increase the chance of developing certain cancers, like checking a home’s blueprint for known structural flaws. It matters to investors because demand for these tests affects companies that make diagnostics, labs, and genetic-data services, and results can influence healthcare costs, insurance decisions, regulatory scrutiny, and the market for preventive treatments and targeted drugs.

pan-cancer medical

"one of the largest pan-cancer registries accessible for research use"

Pan-cancer describes treatments, tests or research that target a common feature found across many different types of tumors rather than a single organ or cancer type. Investors care because a pan-cancer approach can mean a much larger potential market and simpler regulatory path—like a single key that opens many locks—so success can scale revenue and reduce dependence on any one cancer indication.

poster board technical

"Evaluation of the Relationship of Molecular Residual Disease Testing... Poster Board Number: 1590"

A poster board is a large printed display used at conferences or meetings to summarize data, results, or company information in charts, figures and short text so passersby can quickly understand the key points. For investors it matters because these boards often reveal early clinical, technical or strategic information before full reports are released — like a roadside billboard that signals progress or trouble and can affect perceptions and market interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting, including two oral presentations and two posters.

“Having four abstracts accepted at the prestigious SGO annual meeting underscores the importance of the data we are sharing and our commitment to the cancer care continuum,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “We are particularly pleased to be presenting the latest Precise MRD^™ data, showing that Precise MRD testing after adjuvant therapy for ovarian cancer was significantly prognostic of recurrence during the monitoring period. Importantly, recurrence risk tracked with the quantitative ctDNA fraction detected by Precise MRD, with elevated risk observed even at ctDNA levels detectable only by an ultrasensitive assay.”

The remaining three presentations use data from the Myriad Collaborative Research Registry^™ (MCRR), one of the largest pan-cancer registries accessible for research use, including de-identified data for more than 1.3 million participants. The studies demonstrate Myriad’s commitment to externally driven research that addresses diverse questions with immediate clinical implications:

• Germline pathogenic and likely pathogenic variant prevalence is associated with age and ancestry in patients diagnosed with ovarian cancer before age 40;
• Ovarian cancer diagnosis varies by Lynch syndrome gene, informing counseling and risk-reducing surgery recommendations;
• Universal hereditary cancer screening identifies more individuals at high risk for endometrial cancer compared to age-based screening.
  
  

These studies will be presented at the Society of Gynecologic Oncology Annual Meeting on April 10-13 at the Puerto Rico Convention Center in San Juan. Myriad will exhibit at booth #523. For more information, visit: https://myriad.com/oncology/oncology-conferences/

Myriad Genetics Presentations
Precise MRD
Evaluation of the Relationship of Molecular Residual Disease Testing to Ovarian Cancer Recurrence
Poster Board Number: 1590
Sun., April 12 at 12:00-1:00 pm AST
Presenter: John Nakayama, MD, Allegheny Health Network

MCRR
Prevalence of germline pathogenic variants in patients with endometrial cancer diagnosed before and after 65 years old within a laboratory-based research registry
Rapid Fire Oral I: Genetics Prevention and Surgery
Sat., April 11 – 3:05-3:08 pm AST
Presenter: Kieran Seay, MD, University of Pittsburgh Medical Center

Broad landscape of genetic variants and ancestry associated with ovarian cancer before age forty
Poster Board Number: 1450
Sun., April 12 – 4:00-4:45 pm AST
Presenter: Eliya K. Shachar, MD, University of California, Los Angeles

Age at ovarian cancer diagnosis varies by lynch syndrome gene: a genetic testing laboratory registry study
Focused Forum X: Genetics - Keeping up with the Genes
Mon., April 13 – 9:30-10:30 am AST
Presenter: Ying L. Liu, MD, MPH, Memorial Sloan Kettering Cancer Center

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.

Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the studies demonstrate the company’s commitment to externally driven research that addresses diverse questions with immediate clinical implications. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What new findings will MYGN present at the SGO Annual Meeting April 10-13, 2026?

Myriad will present four abstracts, including Precise MRD results linking ctDNA levels to ovarian cancer recurrence. According to the company, three additional studies use the MCRR registry (>1.3 million de-identified participants) addressing germline variant prevalence and hereditary screening.

What does the Precise MRD result announced by MYGN mean for ovarian cancer monitoring?

Precise MRD testing after adjuvant therapy was significantly prognostic of recurrence during monitoring. According to the company, recurrence risk tracked with quantitative ctDNA fraction, with elevated risk seen even at ultrasensitive ctDNA levels.

When and where will Myriad Genetics (MYGN) present at SGO, and where is their exhibit booth?

Myriad's presentations run April 11–13, 2026, at the SGO Annual Meeting in San Juan, Puerto Rico. According to the company, sessions include posters and oral talks, and Myriad will exhibit at booth #523.

What is the Myriad Collaborative Research Registry (MCRR) referenced by MYGN at SGO 2026?

The MCRR is a laboratory-based research registry with de-identified data for more than 1.3 million participants. According to the company, it supports externally driven studies on germline variants and hereditary cancer screening.

Which Myriad presenters and topics are scheduled at the SGO meeting for MYGN?

Presenters include John Nakayama, Kieran Seay, Eliya K. Shachar, and Ying L. Liu on MRD, genetics, and registry analyses. According to the company, topics cover Precise MRD prognostics, germline variant prevalence, Lynch syndrome diagnosis age, and hereditary screening.